267 related articles for article (PubMed ID: 11443562)
61. Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model.
Ottolini MG; Curtis SR; Mathews A; Ottolini SR; Prince GA
Bone Marrow Transplant; 2002 Jan; 29(2):117-20. PubMed ID: 11850705
[TBL] [Abstract][Full Text] [Related]
62. Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals.
Murray J; Saxena S; Sharland M
Arch Dis Child; 2014 May; 99(5):469-73. PubMed ID: 24464977
[TBL] [Abstract][Full Text] [Related]
63. The use of intravenous palivizumab for treatment of persistent RSV infection in children with leukemia.
Santos RP; Chao J; Nepo AG; Butt S; Stellrecht KA; Pearce JM; Lepow ML
Pediatrics; 2012 Dec; 130(6):e1695-9. PubMed ID: 23147965
[TBL] [Abstract][Full Text] [Related]
64. Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience.
Tsitsikas DA; Oakervee H; Cavenagh JD; Gribben J; Agrawal SG; Mattes FM
Br J Haematol; 2009 Sep; 146(5):574-6. PubMed ID: 19538531
[No Abstract] [Full Text] [Related]
65. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection.
Lacaze-Masmonteil T; Seidenberg J; Mitchell I; Cossey V; Cihar M; Csader M; Baarsma R; Valido M; Pollack PF; Groothuis JR;
Drug Saf; 2003; 26(4):283-91. PubMed ID: 12608889
[TBL] [Abstract][Full Text] [Related]
66. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
[TBL] [Abstract][Full Text] [Related]
67. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.
Pediatrics; 1998 Sep; 102(3):531-7. PubMed ID: 9724660
[TBL] [Abstract][Full Text] [Related]
68. Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.
Griffin MP; Khan AA; Esser MT; Jensen K; Takas T; Kankam MK; Villafana T; Dubovsky F
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956428
[TBL] [Abstract][Full Text] [Related]
69. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin.
Ghosh S; Champlin RE; Englund J; Giralt SA; Rolston K; Raad I; Jacobson K; Neumann J; Ippoliti C; Mallik S; Whimbey E
Bone Marrow Transplant; 2000 Apr; 25(7):751-5. PubMed ID: 10745261
[TBL] [Abstract][Full Text] [Related]
70. Effective use of oral ribavirin for respiratory syncytial viral infections in allogeneic haematopoietic stem cell transplant recipients.
Gorcea CM; Tholouli E; Turner A; Saif M; Davies E; Battersby E; Dignan FL
J Hosp Infect; 2017 Feb; 95(2):214-217. PubMed ID: 28077243
[TBL] [Abstract][Full Text] [Related]
71. Intravenous ribavirin for eradication of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and/or gastrointestinal tract in recipients of allogeneic hematopoietic stem cell transplants.
Schleuning M; Buxbaum-Conradi H; Jäger G; Kolb HJ
Hematol J; 2004; 5(2):135-44. PubMed ID: 15048064
[TBL] [Abstract][Full Text] [Related]
72. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections.
Shah DP; Ghantoji SS; Shah JN; El Taoum KK; Jiang Y; Popat U; Hosing C; Rondon G; Tarrand JJ; Champlin RE; Chemaly RF
J Antimicrob Chemother; 2013 Aug; 68(8):1872-80. PubMed ID: 23572228
[TBL] [Abstract][Full Text] [Related]
73. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
[TBL] [Abstract][Full Text] [Related]
74. Translational sciences approach to RSV vaccine development.
Kurzweil V; Tang R; Galinski M; Wang K; Zuo F; Cherukuri A; Gasser RA; Malkin E; Sifakis F; Mendel DB; Esser MT
Expert Rev Vaccines; 2013 Sep; 12(9):1047-60. PubMed ID: 24053398
[TBL] [Abstract][Full Text] [Related]
75. Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution-specific guideline.
McCoy D; Wong E; Kuyumjian AG; Wynd MA; Sebti R; Munk GB
Transpl Infect Dis; 2011 Apr; 13(2):117-21. PubMed ID: 20804534
[TBL] [Abstract][Full Text] [Related]
76. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation.
McCarthy AJ; Kingman HM; Kelly C; Taylor GS; Caul EO; Grier D; Moppett J; Foot AB; Cornish JM; Oakhill A; Steward CG; Pamphilon DH; Marks DI
Bone Marrow Transplant; 1999 Dec; 24(12):1315-22. PubMed ID: 10627641
[TBL] [Abstract][Full Text] [Related]
77. [Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia].
Aliamovskaia GA; Keshinian ES
Vestn Ross Akad Med Nauk; 2012; (12):30, 32-4. PubMed ID: 23530423
[TBL] [Abstract][Full Text] [Related]
78. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
79. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease.
Meissner HC; Groothuis JR; Rodriguez WJ; Welliver RC; Hogg G; Gray PH; Loh R; Simoes EA; Sly P; Miller AK; Nichols AI; Jorkasky DK; Everitt DE; Thompson KA
Antimicrob Agents Chemother; 1999 May; 43(5):1183-8. PubMed ID: 10223933
[TBL] [Abstract][Full Text] [Related]
80. Respiratory syncytial virus infections in children with cancer.
Chemaly RF; Ghantoji SS; Shah DP; Shah JN; El Taoum KK; Champlin RE; Nunez CA; Mulanovich V; Ariza-Heredia E
J Pediatr Hematol Oncol; 2014 Aug; 36(6):e376-81. PubMed ID: 24327130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
